IBJNews

General Growth seeks better offer than Simon's

Back to TopCommentsE-mailPrintBookmark and Share

General Growth Properties Inc. is seeking a higher price, fewer stock warrants or both from Brookfield Asset Management Inc. after its bankruptcy exit plan was matched by Simon Property Group Inc., a person with knowledge of the discussions said.

General Growth, the second-biggest U.S. mall owner, also is continuing to talk with larger rival Simon, said the person, who asked not to be named because the discussions are private. General Growth needs to decide if it will continue to back Brookfield’s plan before a bankruptcy court hearing on the competing proposals, scheduled for April 29.

Indianapolis-based Simon, whose $10 billion takeover offer for General Growth was turned down as too low in February, earlier this week pledged to invest $2.5 billion in a reorganization of the company and match the terms of a plan by Brookfield and partners Fairholme Capital Management LLC and Pershing Square Capital Management LP. Simon said its proposal is better for General Growth shareholders than the Brookfield plan because it doesn’t include issuing warrants that may dilute stock value.

Brookfield “is averse to participating in bidding wars and may not currently feel that it has to,” Cedrik Lachance, a senior analyst at Green Street Advisors in Newport Beach, Calif., wrote in a note to investors Thursday night. “However, the mathematics of recapitalizing GGP at higher prices suggests that there is room for a higher bid.”

Hedge fund Paulson & Co. pledged to invest $1 billion as part of the proposal by Simon. General Growth said this week that it will study the new offer.

Katherine Vyse, a spokeswoman for Brookfield, declined to comment. Les Morris, a Simon spokesman, didn’t immediately return a phone message seeking comment.

To win backing from General Growth, Simon needs to explain its planned strategy for the company, the person familiar with the talks said. Given that Simon would own a large stake in its biggest rival, akin to Coca-Cola Co. investing in PepsiCo Inc., the company needs to lay out details of its multi-year business plan for General Growth, the person said.

Simon, the largest U.S. mall owner, said this week it’s still willing to buy Chicago-based General Growth outright. The $6.55 billion plan by the Brookfield-led group seeks so-called stalking horse status at the April 29 hearing and would include issuing stock warrants if the proposal is approved by the court, increasing the price of any future takeover by another bidder.

General Growth would emerge from bankruptcy as an independent company under both the Brookfield plan and Simon’s new offer. The mall owner filed the largest real estate bankruptcy in U.S. history one year ago after amassing $27 billion in debt making acquisitions. Its properties include New York’s South Street Seaport, Boston’s Faneuil Hall and the Grand Canal Shoppes and Fashion Show in Las Vegas.

Simon would buy 250 million shares at $10 each under its new offer, which it said is the same amount Toronto-based Brookfield would acquire under its plan and at the same price. It would also agree to the same terms as Brookfield’s proposal for the recapitalization of the company and planned spinoff of a new entity, David Simon wrote in an April 14 letter to General Growth CEO Adam Metz.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. So, Pence wants the federal government to ignore the 2008 law that allows children from these countries to argue for asylum in front of a judge. How did this guy become governor? And how is that we'll soon be subjected to repeatedly seeing him on TV being taken seriously as a presidential candidate? Am I in Bizzaro-U.S.A.?

  2. "And the most rigorous studies of one-year preschool programs have shown short-term benefits that fade out in a few years or no benefits at all." So we are going down a path that seems to have proven not to work very well. Right intention, wrong approach?

  3. Well for Dunkin Donuts it might say that even a highly popular outlet can't make a poorly sited location work. That little strip has seen near constant churn for years.

  4. Years ago, the Pharmaceutical and Medical Device companies shifted their research investment away from Medical Institutions to focus more on private research centers, primarily because of medical institution inefficiencies in initiating clinical studies and their inability/commitment to enroll the needed number of patients in these studies. The protracted timelines of the medical institutions were prompting significant delays in the availability of new drug and medical device entities for patients and relatedly, higher R and D expenditures to the commercial industry because of these delays. While the above stated IU Health "ratio is about $2.50 in federal funding for every $1 in industry funding", the available funding is REVERSED as commercial R and D (primarily Phase I-IV clinical work)runs $2.50 to $1 for available federal funding ($76.8B to $30.9B in 2011). The above article significatly understated the available R and D funding from industry......see the Pharma and Medical Device industry websites. Clearly, if medical institutions like IU Health wish to attract more commercial studies, they will need to become more competitive with private clinical sites in their ability to be more efficient and in their commitment to meet study enrollment goals on time. Lastly, to the reference to the above Washington Post article headlined “As drug industry’s influence over research grows, so does the potential for bias", lacks some credibility as both FDA and Institutional Institutional Review Boards must approve the high proportion of these studies before studies are started. This means that both study safety and science must be approved by both entities.

  5. ChIeF and all the other critics – better is better no matter what. Get over it; they are doing better despite you ?

ADVERTISEMENT